Abstract:The association of cdk4 with D-type cyclins to form functional kinase complexes is comparatively inefficient. This has led to the suggestion that assembly might be a regulated step. In this report we demonstrate that the CDK inhibitors p21(CIP), p27(KIP), and p57(KIP2) all promote the association of cdk4 with the D-type cyclins. This effect is specific and does not occur with other cdk inhibitors or cdk-binding proteins. Both in vivo and in vitro, the abundance of assembled cdk4/cyclin D complex increases directly with increasing inhibitor levels. The promotion of assembly is not attributable to a simple cell cycle block and requires the function of both the cdk and cyclin-binding domains. Kinetic studies demonstrate that p21 and p27 lead to a 35- and 80-fold increase in K(a), respectively, mostly because of a decrease in K(off). At low concentrations, p21 promotes the assembly of active kinase complexes, whereas at higher concentrations, it inhibits activity. Moreover, immunodepletion experiments demonstrate that most of the active cdk4-associated kinase activity also associates with p21. To confirm these results in a natural setting, we examine the assembly of endogenous complexes in mammary epithelial cells after release from a G(0) arrest. In agreement with our other data, cyclin D1 and p21 bind concomitantly to cdk4 during the in vivo assembly of cdk4/cyclin D1 complexes. This complex assembly occurs in parallel to an increase in cyclin D1-associated kinase activity. Immunodepletion experiments demonstrate that most of the cellular cyclin D1-associated kinase activity is also p21 associated. Finally, we find that all three CIP/KIP inhibitors target cdk4 and cyclin D1 to the nucleus. We suggest that in addition to their roles as inhibitors, the p21 family of proteins, originally identified as inhibitors, may also have roles as adaptor proteins that assemble and program kinase complexes for specific functions.

p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21

Expression of Protein P27 is Associated with Progression and Prognosis in Laryngeal Cancer

Inhibition of Cyclin-Dependent Kinases by P21.

Expression of P27 is Associated with Bax Expression and Spontaneous Apoptosis in Oral and Oropharyngeal Carcinoma

A Novel Cycline/cyclina-Cdk Inhibitor Targets P27(kip1) Degradation, Cell Cycle Progression and Cell Survival: Implications in Cancer Therapy.

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1

A cell cycle-regulated inhibitor of cyclin-dependent kinases.

P57(Kip2), A Structurally Distinct Member of the P21(Cip1) Cdk Inhibitor Family, is A Candidate Tumor-Suppressor Gene

New functional activities for the p21 family of CDK inhibitors.

A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons

Regulation of P27kip1 Phosphorylation and G1 Cell Cycle Progression by Protein Phosphatase PPM1G.

Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F

Identification of Human and Mouse P19, a Novel CDK4 and CDK6 Inhibitor with Homology to P16ink4

p21 in cancer: intricate networks and multiple activities

[Prognostic Significance of Cyclin-Dependent Kinase Inhibitor P27kip1 Expression in Human Breast Cancer].

The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo

Effect of P27(Kip1) on Cell Cycle and Apoptosis in Gastric Cancer Cells

[Expression of Cyclin D1 and P27kip1 in Renal Cell Carcinoma and Its Significance].

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer

Involvement of P21 and P27 in the Regulation of CDK Activity and Cell Cycle Progression in the Regenerating Liver.